Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease

[1]  D. Jiang,et al.  Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease , 2005, Journal of Neural Transmission.

[2]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[3]  Z. Harris.  Aceruloplasminemia , 2003, Journal of the Neurological Sciences.

[4]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  S. Melov.  ‘…and C is for Clioquinol’ – the AβCs of Alzheimer's disease , 2002, Trends in Neurosciences.

[6]  L. Tremblay,et al.  Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.

[7]  E. Sato,et al.  [Reactive oxygen]. , 2002, Nihon eiseigaku zasshi. Japanese journal of hygiene.

[8]  P. Sharma,et al.  Release of iron from ferritin by metabolites of benzene and superoxide radical generating agents. , 2001, Toxicology.

[9]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[11]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease , 2001 .

[12]  J. Connor,et al.  Iron and iron management proteins in neurobiology. , 2001, Pediatric neurology.

[13]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[14]  K Takada,et al.  A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. , 2001, American journal of human genetics.

[15]  F. Torti,et al.  Ferritin and the response to oxidative stress. , 2001, Biochemical Journal.

[16]  J. Connor,et al.  Iron and neurodegenerative disorders , 2001, Brain Research Bulletin.

[17]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[18]  M. Beal,et al.  Experimental models of Parkinson's disease , 2001, Nature Reviews Neuroscience.

[19]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[20]  Shigeyoshi Fujisawa,et al.  XAFS spectroscopy of a single neuron from a patient with Parkinson's disease , 2001 .

[21]  S. Korsmeyer,et al.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Shigeyoshi Fujisawa,et al.  XANES spectroscopy of a single neuron from a patient with Parkinson's disease. , 2001, Journal of synchrotron radiation.

[23]  J. Andersen.  Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? , 2001, Novartis Foundation symposium.

[24]  J. Tateishi,et al.  Subacute myelo‐optico‐neuropathy: Clioquinol intoxication in humans and animals , 2000, Neuropathology : official journal of the Japanese Society of Neuropathology.

[25]  A. Albertini,et al.  Overexpression of Wild Type and Mutated Human Ferritin H-chain in HeLa Cells , 2000, The Journal of Biological Chemistry.

[26]  E. Morgan,et al.  Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. , 2000, Cellular and molecular biology.

[27]  J. Connor,et al.  Iron deficiency alters H- and L-ferritin expression in rat brain. , 2000, Cellular and molecular biology.

[28]  A. Bush,et al.  Metals and neuroscience. , 2000, Current opinion in chemical biology.

[29]  L. Oreland,et al.  Changes in uptake of vitamin B12 and trace metals in brains of mice treated with clioquinol , 2000, Journal of the Neurological Sciences.

[30]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[31]  O. Andreassen,et al.  Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.

[32]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.

[33]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[34]  Juliek . Andersen,et al.  The Role of Iron in Parkinson Disease and 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity , 1999, IUBMB life.

[35]  W. Whelan.  A Welcome to IUBMB Life , 1999 .

[36]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[37]  T. Morgan,et al.  The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction , 1999, Neuroscience.

[38]  K. Jellinger,et al.  The Role of Iron in Neurodegeneration , 1999, Drugs & aging.

[39]  J. Parks,et al.  The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. , 1999, Biochimica et biophysica acta.

[40]  C. Palmer,et al.  Cellular distribution of ferritin subunits in postnatal rat brain , 1998, The Journal of comparative neurology.

[41]  P. Riederer,et al.  In Vitro Studies of Ferritin Iron Release and Neurotoxicity , 1998, Journal of neurochemistry.

[42]  C. Chiueh,et al.  Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons. , 1998, Advances in pharmacology.

[43]  H. Hung,et al.  MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. , 1998, Free radical biology & medicine.

[44]  J. Allman,et al.  Topographical localization of iron in brains of the aged fat‐tailed dwarf lemur (Cheirogaleus medius) and gray lesser mouse lemur (Microcebus murinus) , 1998, American journal of primatology.

[45]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Youdim,et al.  The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. , 1997, Pharmacology & toxicology.

[47]  G. Bartzokis,et al.  MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.

[48]  M. Beal,et al.  Mitochondria and free radicals in neurodegenerative diseases , 1997 .

[49]  J. Connor.  Metals and Oxidative Damage in Neurological Disorders , 1997, Springer US.

[50]  F. Torti,et al.  Role of H and L Subunits in Mouse Ferritin* , 1996, The Journal of Biological Chemistry.

[51]  P. Harrison,et al.  The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.

[52]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[53]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[54]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[55]  P. Jenner.  Oxidative damage in neurodegenerative disease , 1994, The Lancet.

[56]  M. Beal,et al.  Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1994, Brain Research.

[57]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[58]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[59]  S. Benkovic,et al.  Isoforms of ferritin have a specific cellular distribution in the brain , 1994, Journal of neuroscience research.

[60]  J. Connor,et al.  Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain , 1993, The Journal of comparative neurology.

[61]  P. Enrico,et al.  Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine (MPTP)-treated rat , 1993, Neuroscience Letters.

[62]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[63]  Mark J. West,et al.  Regionally specific loss of neurons in the aging human hippocampus , 1993, Neurobiology of Aging.

[64]  J. Beard,et al.  Brain iron: location and function. , 1993, Progress in food & nutrition science.

[65]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[66]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[67]  M. Brilliant,et al.  5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[69]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[70]  S. Yoshimura,et al.  The same chemicals induce different neurotoxicity when administered in high doses for short term or low doses for long term to rats and dogs. , 1992, Molecular and chemical neuropathology.

[71]  J. Gutteridge,et al.  Iron and oxygen radicals in brain , 1992, Annals of neurology.

[72]  S. Bondy,et al.  Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. , 1992, Neurotoxicology.

[73]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[74]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[75]  M. Marciani,et al.  Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. , 1991, Haematologica.

[76]  J. Adams,et al.  Oxygen free radicals and Parkinson's disease. , 1991, Free radical biology & medicine.

[77]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[78]  J. Langston,et al.  MPTP‐induced parkinsonism as a model for Parkinson's disease , 1989, Acta neurologica Scandinavica. Supplementum.

[79]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[80]  E. Huehns,et al.  11 The toxic effects of desferrioxamine , 1989 .

[81]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[82]  M. Hentze,et al.  The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. , 1988, The Journal of biological chemistry.

[83]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[84]  M. Hentze,et al.  Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Voon Wee Yong,et al.  Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.

[86]  V. Yong,et al.  Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment , 1986, Neuroscience Letters.

[87]  R. Switzer,et al.  The regional distribution and cellular localization of iron in the rat brain , 1984, Neuroscience.

[88]  P. Thomas,et al.  Neurotoxicity of halogenated hydroxyquinolines. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[89]  F. Clifford Rose,et al.  Clioquinol neurotoxicity: an overview. , 1984, Acta neurologica Scandinavica. Supplementum.

[90]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[91]  O. Griffith,et al.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. , 1980, Analytical biochemistry.

[92]  O. Hallén.  [Subacute myelo-optico-neuropathy]. , 1980, Der Nervenarzt.

[93]  P. Thomas,et al.  Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[94]  T. Meade.  Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. , 1975, British journal of preventive & social medicine.

[95]  M. H. Joseph,et al.  TRYPTOPHAN PLUS A PYRROLASE INHIBITOR FOR DEPRESSION ? , 1975, The Lancet.

[96]  喜徳 喜谷,et al.  5-クロロ-7-ヨード-8-キノリノール金属キレートの質量分析 , 1974 .

[97]  R. Kono,et al.  Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. , 1973, Lancet.

[98]  T. Tsubaki,et al.  Neurological syndrome associated with clioquinol. , 1971, Lancet.